Use of oleuropein and hydroxytyrosol to prevent neonatal hypoxic-ischemic encephalopathy

Pretreatment with oleuropein or hydroxytyrosol effectively protects the neonatal brain from hypoxic-ischemic encephalopathy by reducing brain damage through antioxidant and anti-inflammatory actions, offering a less invasive alternative to therapeutic hypothermia.

WO2025262356A1 Publication Date: 2025-12-26SERVICIO ANDALUZ DE SALUD (SAS) +1
0 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2025/070364
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-20
Filing Date
2025-06-19
Publication Date
2025-12-26

AI Technical Summary

Technical Problem

Current treatments for neonatal hypoxic-ischemic encephalopathy, such as therapeutic hypothermia, do not provide complete neuroprotection, and there is a need for novel, less invasive strategies to prevent or reduce brain damage from hypoxic-ischemic events in newborns.

Method used

Pretreatment with oleuropein (Ole) or its metabolite hydroxytyrosol (Htyr) is administered to neonates via intraperitoneal or maternal routes to protect the brain from hypoxic-ischemic encephalopathy, utilizing their antioxidant, anti-inflammatory, and anti-apoptotic properties to reduce histological and cellular damage.

Benefits of technology

Pretreatment with Ole or Htyr demonstrates dose-dependent neuroprotection in an in vivo model of neonatal HI encephalopathy, reducing brain damage without the need for therapeutic hypothermia, increasing accessibility, and providing a less invasive treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the use of oleuropein (Ole) and the active metabolite thereof, hydroxytyrosol (Htyr) to prevent neonatal hypoxic-ischemic encephalopathy (HIE). Pretreatment with Ole and / or Htyr provides dose-dependent neuroprotection in an in vivo model of neonatal hypoxic-ischemic encephalopathy. Described are compositions comprising oleuropein and / or hydroxytyrosol for use in preventing this disease, both for direct administration to the foetus and / or newborn, and for administration via the mother during pregnancy and / or breastfeeding.
Need to check novelty before this filing date? Find Prior Art